This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pamela's Most Recent Article

Pfizer Ponies Up to Develop Long-acting Growth Hormone

12/16/14 - 11:38 AM EST

Opko gains $295 million up front for global license to develop, market long-acting HGH.

read more >

Other Articles by Pamela

Free Reports

Third Point's Daniel Loeb Tells Amgen it's Time to Break up Third Point's Daniel Loeb Tells Amgen it's Time to Break up

10/22/14 - 11:36 AM EDT

Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.

read more >
Changing hospital dynamic leads Becton Dickinson to buy CareFusion Changing hospital dynamic leads Becton Dickinson to buy CareFusion

10/06/14 - 02:28 PM EDT

Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.

read more >
Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B

09/29/14 - 11:13 AM EDT

Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.

read more >
Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid Auxilium Adopts Poison Pill in Response to $2.2B Endo Bid

09/17/14 - 11:50 AM EDT

The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.

read more >
Cognizant Expands Healthcare Information Technology With $2.7B Trizetto Buy Cognizant Expands Healthcare Information Technology With $2.7B Trizetto Buy

09/15/14 - 11:08 AM EDT

Teaneck, N.J.-based information technology solutions company Cognizant Technology Solutions is adding the operations of TriZetto to create a fully integrated healthcare technology and operations leader.

read more >
Roche, InterMune a Strategic Play in Midst of Inversions Roche, InterMune a Strategic Play in Midst of Inversions

08/27/14 - 09:19 AM EDT

As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.

read more >
Pfizer Bolsters Injectables by Buying InnoPharma Pfizer Bolsters Injectables by Buying InnoPharma

07/17/14 - 10:17 AM EDT

Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.

read more >
St. Jude Medical Pays $200M for NeuroTherm St. Jude Medical Pays $200M for NeuroTherm

07/15/14 - 09:44 AM EDT

Target produces radiofrequency ablation systems, boosting the buyer's pain management business.

read more >
Salix to Invert, Merging With Cosmo Pharma Salix to Invert, Merging With Cosmo Pharma

07/09/14 - 01:05 PM EDT

Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.

read more >
Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs